🇺🇸 FDA
Patent

US 12054537

Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12054537 (Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies) held by Inovio Pharmaceuticals, Inc. expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Inovio Pharmaceuticals, Inc.
Grant date
Tue Aug 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/51, A61K2039/53